ENYO Pharma
ENYO Pharma is a clinical-stage biotechnology company focused on developing FXR agonists for the treatment of severe kidney diseases. They are currently conducting a Phase 2 trial (ALPESTRIA-1) of Vonafexor in Alport syndrome patients, a rare genetic kidney disease. The company also plans to initiate two new clinical programs with the new funding.
Funding Round: Series C
Funding Amount: €32M
Date: 12-Jun-2025
Investors: Vesalius Biocapital IV, OrbiMed, Morningside, AndEra, BPIFrance (InnoBio and Large Venture), Sofinnova Partners
Markets: Biotech, Healthcare
HQ: Lyon, France
Founded: 2014
Website: https://www.enyopharma.com/
LinkedIn: https://www.linkedin.com/company/enyo-pharma
Twitter: https://twitter.com/enyopharma
Crunchbase: https://www.crunchbase.com/organization/enyo-pharma
Leave a Comment
Comments
No comments yet.